High Impact Growth Revvity’s strong revenue trajectory and large-scale TB testing platform developments (T-SPOT A201 and T-SPOT.TB) indicate rising demand for high-throughput diagnostic automation. This suggests sales opportunities with large clinical laboratories and public health networks seeking scalable TB and infectious disease solutions.

Strategic Partnerships Recent partnerships and distributor agreements (e.g., Alithea Genomics collaboration for MERCURIUS DRUG-seq) point to a channel strategy that accelerates market reach. Target collaborations with genomics, drug discovery, and contract research organizations to expand software and platform adoption.

Software Expansion Expansion of the Signals software portfolio and launch of Signals for Startups signals a shift toward enterprise-ready informatics and scalable data management. This creates opportunities to upsell integrated data workflows, design environments, and analytics services to biotechs and research institutions.

Global Scale With revenue of billions reported across 160+ countries and a diverse customer base including pharma, diagnostics, academia, and government, there is a broad market receptive to Revvity’s high-throughput platforms and integrated tech stack. Focus on multinational labs and cross-border collaborations for large contract wins.

Innovation Momentum Frequent product development in automated testing, high-throughput platforms, and advanced analytics indicates ongoing innovation. Sales plays should emphasize deployment speed, reliability, and total cost of ownership benefits to labs upgrading from legacy systems or expanding capacity.